CLASS II ONGOING Drug recall · Reported 1 Aug 2018 · FDA Enforcement Report

Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 320 mg recalled

Teva Pharmaceuticals USA is recalling Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 320 mg/, USP, distributed nationwide in the US. The recall was initiated on 16 Jul 2018 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot Numbers: 1191188M, 1191189M, 1191190M, 1199220M, 1217576M, 1217577M, 1217578M, 1220832M, 1220833M, 1247283M, 1247284M, 1247285M, 1247286M, 1247287A, 1280632M, 1280633M
Quantity recalled164,922 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0985-2018
FDA event ID
80538
Recalling firm
Teva Pharmaceuticals USA, North Wales, PA
Classification
Class II
Status
Ongoing
Recall initiated
16 Jul 2018
FDA classified
24 Jul 2018
Reported
1 Aug 2018
Type
Voluntary: Firm initiated
Customers notified by
Press Release
Reason category
Potency & Assay

Timeline

16 Jul 2018Recall initiated by company
24 Jul 2018Classified by FDA+8 days
1 Aug 2018Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 320 mg/25 mg tablets, USP, 90-count bottle, Rx Only, Rx Only, Manufactured by: Arrow Pharma (Malta) Ltd. India, Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054. NDC 0591-2318-19.

Where it was distributed

Product was distributed throughout the United States, including Hawaii and Puerto Rico

Nationwide HawaiiPuerto Rico

Questions about this recall

Why was it recalled?

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Which lots are affected?

Lot Numbers: 1191188M, 1191189M, 1191190M, 1199220M, 1217576M, 1217577M, 1217578M, 1220832M, 1220833M, 1247283M, 1247284M, 1247285M, 1247286M, 1247287A, 1280632M, 1280633M

Where was it sold?

Product was distributed throughout the United States, including Hawaii and Puerto Rico

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

8 other products · FDA event 80538

This product is part of a recall event; the main page for the event is Valsartan and Hydrochlorothiazide (HCTZ) Tablets recalled.

More recalls from Teva Pharmaceuticals USA

All 280

Other Valsartan recalls

All 88